Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Scavenger Receptor Type B1 Is Essential for High Density Lipoprotein Nanoparticle Induced B-Cell Lymphoma Cell Death

Jonathan Scott Rink, PhD, Shuo Yang, Osman Cen, Fei Ying, Young Kwang Chae, MD MPH, Denise Scholtens, Jonathan Moreira, MD, Amy Chadburn, MD, Leo I. Gordon, MD, Colby Shad Thaxton

Blood (2015) 126 (23): 2756.

https://doi.org/10.1182/blood.V126.23.2756.2756

Published: 2015

Journal Articles

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Young Kwang Chae, MD, MPH, Hagop M Kantarjian, MD, Muhamed Baljevic, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Susan O'Brien, MD, Carlos G. Romo, M.D., Sherry R. Pierce, RN, BS, Elias Jabbour, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2724.

https://doi.org/10.1182/blood.V122.21.2724.2724

Published: 2013

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

Young Kwang Chae, MD, MPH, Hagop M. Kantarjian, MD, Carlos G. Romo, M.D., Clay Whitaker, Elias J. Jabbour, MD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Farhad Ravandi, MD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3786.

https://doi.org/10.1182/blood.V120.21.3786.3786

Published: 2012

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Young Kwang Chae, MD, MPH, Long Xuan Trinh, Michael J. Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 2904.

https://doi.org/10.1182/blood.V120.21.2904.2904

Published: 2012

Journal Articles

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

Young Kwang Chae, MD, MPH, Nianxiang Zhang, Yihua Qiu, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Kevin R. Coombes, PhD, Steven M. Kornblau, MD, PhD

Blood (2012) 120 (21): 891.

https://doi.org/10.1182/blood.V120.21.891.891

Published: 2012

Journal Articles

Financial Conflicts of Interest Are Common and Frequently Influence Conclusions of Economic Analyses Presented at the American Society of Hematology Annual Meeting.

Sekwon Jang, MD, Young Kwang Chae, MD, MPH, MBA, Navneet S. Majhail, MD, MS

Blood (2009) 114 (22): 810.

https://doi.org/10.1182/blood.V114.22.810.810

Published: 2009

Journal Articles

The Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of Developing Venous Thromboembolism in Patients with Atherosclerotic Disease.

Young Kwang Chae, MD, MPH, MBA, Danai Khemasuwan, MD, Lakshmi Chebrolu, MD, Shikha Gupta, MD, Stefan Neagu, Alejandra Carpio, Jongoh Kim, Alan L. Friedman, MD

Blood (2009) 114 (22): 1078.

https://doi.org/10.1182/blood.V114.22.1078.1078

Published: 2009

NARROW

Scavenger Receptor Type B1 Is Essential for High Density Lipoprotein Nanoparticle Induced B-Cell Lymphoma Cell Death

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

Financial Conflicts of Interest Are Common and Frequently Influence Conclusions of Economic Analyses Presented at the American Society of Hematology Annual Meeting.

The Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of Developing Venous Thromboembolism in Patients with Atherosclerotic Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only